Keywords: genentech, sees, rise, 1st-qtr, profits, strong, cancer

Genentech sees 48% rise in 1st-qtr profits on strong cancer drug sales

Article | 24 April 2006

US biotechnology major Genentech, which is majority-owned by Swiss drugmaker Roche, presented a stompingly-good set of first quarter 2006 results, boosted ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Genentech

Roche

Go to company listing

Related Drugs

Rituximab

Rituxan

Avastin

bevacizumab

trastuzumab

Go to drug listing